Connect with us

Politics

Congress To Hold Hearing Focused On Psychedelic Therapy For Military Veterans This Week

Published

on

A congressional committee is scheduled to hold a hearing about increasing military veterans’ access to psychedelic treatments this week—with officials from the U.S. Department of Veterans Affairs (VA) set to testify alongside medical professionals and researchers.

The hearing—titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward”—will be held before the House Veterans’ Affairs Subcommittee on Health on Wednesday.

Andrew Gradison, a senior advisor to the under secretary for health at the VA’s Veterans Health Administration (VHA), said in written testimony posted by the panel that President Donald Trump’s administration “has taken decisive action to accelerate psychedelic research and eliminate regulatory obstacles that have historically slowed progress.”

He cited an executive order Trump signed in April with the aim of expediting psychedelic therapy access, saying it was the “first EO in American history dedicated specifically to accelerating clinical research and regulatory review of psychedelics, underscoring the president’s firm commitment to advancing emerging treatments for serious mental illnesses.”

Since then, “VA’s psychedelics research portfolio has grown substantially in response, and our interagency partnerships are driving rapid and safe scientific advancement,” Gradison said, noting that it is now conducting 21 active clinical studies on psychedelics to treat mental health conditions.

He specifically cited a clinical trial VA announced in August to investigate whether psilocybin can help military veterans who are struggling with treatment-resistant depression.

“VA strives to lead the Nation in exploring the therapeutic potential of psychedelic drugs,” Gradison said, adding that the department recognizes that substances such as psilocybin, MDMA and ibogaine “offer promising potential for the complex mental health conditions affecting many of the Veterans we treat.”

The VA official also touted a memorandum of understanding his department signed with the Department of Health and Human Services (HHS) in July outlining a partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions.

The agreement, he said “lays the groundwork for unprecedented VA-HHS operational cooperation on psychedelic trials.”

“As we prepare for potential clinical implementation, VA remains anchored in three core priorities: first, ensuring Veteran safety above all else; second, building a rigorous body of evidence to determine which treatments work for which Veterans; and third, laying the foundation so that, pending all regulatory approvals, VA is positioned to be the first health care system in the Nation to deliver these treatments to Veterans. These priorities shape every research, clinical, and policy decision we make in this space.”

Gradison said VA has already identified 10 facilities “with the expertise, physical space, and operational capacity needed to serve as early implementers, educators, or sites-in-training” with teams that are “experienced in psychedelic research protocols and are preparing to translate that experience into clinical care that maximizes Veterans’ safety if treatments are approved.”

The VA official emphasized, however, that the department discourages self-medicating with psychedelics or using them to replace other mental health treatment options.

Also testifying at Wednesday’s hearing will be Leith States, a former HHS acting assistant secretary for health who now runs the consulting firm States Strategies.

He is calling on Congress to support psychedelic research that “answers the clinical questions veterans and clinicians face,” while requiring VA to set and track milestones for clinical readiness and access and holding the department accountable for patient safety and lasting improvement in veterans’ lives.

“Doing our duty means investigating promising treatments with urgency and discipline, speaking plainly about what we know, and preparing the people and systems needed to deliver responsible, safe, and ethical care,” States’s testimony said. “Veterans’ needs should determine our priorities as we build on useful work across administrations, examine shortcomings honestly, and sustain the progress clinicians and researchers need to improve care.”

The testimony of Marion Coe of Pinney Associates references her work to compile responses to a request for information (RFI) the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus issued seeking input from experts about how to best set up a regulatory framework for psychedelic medicines.

Among other points, she emphasized that VA must “begin preparing its clinical infrastructure and workforce” before Food and Drug Administration (FDA) approval of any psychedelic treatments “if it is to be ready to expand access as rapidly and as safely possible.”

“The central challenge is not simply whether these medicines can work,” Coe said. “It is whether we can build the infrastructure necessary to deliver them safely, ethically, and to the veterans who need them, and help as many patients who could benefit as safety and other considerations allow.”

Mark Niciu, an assistant professor at the University of Iowa, used his testimony to explain his research addressing what he called the “major hurdle” of functional unblinding in psychedelic research, which is when participants and evaluators are able to tell which subjects are in the control or experimental group during a trial.

“Expectancy bias is particularly salient in psychedelic medicine trials, where the drug’s effects are acute, intense, highly salient, and reinforced, for example, by the recent re-galvanization of classical psychedelics by the media, government, etc.,” he said. “When such drugs are compared with an inert or insufficiently matched placebo, participants and researchers immediately and accurately know their randomization assignment. In other words, there is ‘double’ functional unblinding, potentially affecting the thoughts and/or behaviors of both parties for the remainder of the trial.”

Raquel Halfond, the senior director of evidence-based practice and health equity at the American Psychological Association, emphasized in her testimony the need for focus on transparency and accountability, infrastructure and associated therapy and workforce demands.

“Each of these areas is necessary to make veteran protection and safety the utmost priority,” she said.

The organization “encourages VA and all federal partners to adopt a stepped, interdisciplinary care model regarding the development of psychedelic-assisted therapy following rigorous and ethical research, with national minimum competencies; independent medical and psychological assessments; strong ethical safeguards and informed consent; on-site human monitoring; structured follow-up; and drug-specific staffing requirements,” Halfond said. “With strong VA research standards and clinical trial protocols being put in place, we are encouraged by the ability of the VA to lead the way with scientific rigor and integrity.”

While not testifying in person at the hearing, Disabled American Veterans, Veterans of Foreign Wars, Special Forces Foundation and Mindbloom all submitted written statements for the record.

Photo courtesy of Mark Groeneveld.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Become a patron at Patreon!

Tom Angell is the editor of Marijuana Moment. A 25-year veteran in the cannabis and drug law reform movement, he covers the policy, politics, science and culture of marijuana, psychedelics and other substances. He previously reported for Forbes, Marijuana.com and MassRoots, and was given the Hunter S. Thompson Media Award by NORML and has been named Journalist of the Year by Americans for Safe Access. As an activist, Tom founded the nonprofit Marijuana Majority and handled media relations, campaigns and lobbying for Law Enforcement Against Prohibition and Students for Sensible Drug Policy.

Advertisement

Marijuana News In Your Inbox

Get our daily newsletter.

Support Marijuana Moment

Add Marijuana Moment as a preferred source on Google.

Marijuana News In Your Inbox

 

Get our daily newsletter.